• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Citigroup initiated coverage on 9 Meters Biopharma with a new price target

    6/4/21 7:33:28 AM ET
    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NMTR alert in real time by email
    Citigroup initiated coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $3.00
    Get the next $NMTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NMTR

    DatePrice TargetRatingAnalyst
    7/8/2021$5.00Outperform
    BMO Capital Markets
    More analyst ratings

    $NMTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

      RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti

      5/30/23 9:25:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

      RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2

      5/15/23 5:15:00 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

      RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136

      4/5/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics
    • 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

      Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief

      1/18/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

      RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's

      1/3/22 7:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sensenig Bethany

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      4/21/23 5:08:33 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sirgo Mark A

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:35:29 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rice Yehuda Michael

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:28:24 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Financials

    Live finance-specific insights

    See more
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022

      Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe

      11/8/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

      Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe

      8/15/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

      On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is

      5/16/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/7/24 7:40:26 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/9/23 11:51:13 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 9 Meters Biopharma Inc.

      SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/8/22 4:57:05 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on 9 Meters Biopharma with a new price target

      BMO Capital Markets initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $5.00

      7/8/21 7:33:42 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on 9 Meters Biopharma with a new price target

      Citigroup initiated coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $3.00

      6/4/21 7:33:28 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brookline Capital resumed coverage on 9 Meters Biopharma with a new price target

      Brookline Capital resumed coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $6.00

      3/25/21 11:52:35 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by 9 Meters Biopharma Inc.

      25-NSE - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      9/8/23 10:11:45 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by 9 Meters Biopharma Inc.

      144 - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/19/23 4:41:57 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      7/18/23 8:00:11 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care